Sectoral joins eFFECTOR Therapeutics Series B round
eFFECTOR Therapeutics Inc, a biopharmaceutical company developing novel cancer treatments, increased its Series B financing to a total of $56 million. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. In conjunction with the increase, Sectoral partner Maha Katabi, PhD, CFA, will join eFFECTOR’s board.
19 February 2016•3 mins read
